10-Q: ALX Oncology Reports Q2 2026 Results, Focuses on Pipeline

ALX Oncology Holdings Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses but a strengthened cash position following recent equity raises.

Summary

• ALX Oncology Holdings Inc. reported its financial results for the second quarter ended June 30, 2026.
• The company incurred a net loss of $17.97 million for the quarter, compared to a net loss of $25.95 million in the same period last year.
• For the six months ended June 30, 2026, the net loss was $35.9 million, a decrease from $56.7 million in the prior year period.
• Research and development expenses decreased by 27% to $13.14 million for the quarter and by 36% to $26.74 million for the six months.
• General and administrative expenses also decreased by 6% for the quarter and 22% for the six months.
• The company's cash, cash equivalents, and investments totaled $153.4 million as of June 30, 2026.
• ALX Oncology has a limited operating history and no products approved for commercial sale, relying on ongoing clinical trials for its product candidates, evorpacept and ALX2004.
• The company anticipates needing substantial additional capital to finance its operations and expects to continue incurring significant net losses.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to continued net losses and significant ongoing R&D expenses, although the company has bolstered its cash position through recent equity offerings.

Positives

• Net loss decreased year-over-year for both the three-month and six-month periods.
• Research and development expenses were reduced by 27% for the quarter and 36% for the six months.
• General and administrative expenses also saw a reduction.
• The company's cash, cash equivalents, and investments increased to $153.4 million.
• The company believes its existing capital resources are sufficient to fund projected operating requirements for at least the next twelve months.
• The company regained compliance with the Nasdaq minimum bid price requirement.

Negatives

• The company incurred a net loss of $17.97 million in Q2 2026 and $35.9 million in the first half of 2026.
• The company has an accumulated deficit of $758.7 million as of June 30, 2026.
• ALX Oncology has no products approved for commercial sale and has not generated any revenue from product sales.
• The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future.
• The company will require substantial additional capital to finance its operations, and such capital may not be available on favorable terms.
• The company's lead product candidate, evorpacept, has not completed a pivotal trial.
• The company's stock price has experienced volatility and previously faced delisting concerns due to minimum bid price requirements.

Risks

• The company has incurred significant net losses since inception and expects to continue incurring significant net losses for the foreseeable future.
• Substantial additional capital will be required to finance operations, and this capital may not be available when needed or on favorable terms.
• The company has a limited operating history, no products approved for commercial sale, and has not generated revenue from product sales, licenses, or collaborations.
• The company is substantially dependent on the success of its lead product candidate, evorpacept, which is in clinical development and has not completed a pivotal trial.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and results may not satisfy regulatory requirements.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, and may fail to demonstrate adequate safety, efficacy, and potency.
• Product candidates may cause significant adverse events or other undesirable side effects.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, potentially leading to an inability to generate product revenue.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it advances its product candidates through clinical trials and seeks regulatory approval. Management believes its current capital resources will fund operations through the first half of 2028, but anticipates the need for substantial additional capital.

Management Comments

• We believe our existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months after the date the condensed consolidated financial statements are issued.
• We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.
• We will require substantial additional capital to finance our operations, and such capital may not be available to us when needed or may only be available on terms that are unfavorable to us.

Industry Context

StockSavvy.ai notes that ALX Oncology operates in the highly competitive clinical-stage biotechnology sector, focusing on immuno-oncology therapies. The company's strategy of combining its lead candidate, evorpacept, with other anti-cancer agents aligns with industry trends aiming to enhance treatment efficacy. However, the significant R&D expenses and ongoing net losses are typical for companies at this stage, with success heavily reliant on clinical trial outcomes and regulatory approvals.

Comparison to Industry Standards

• Many clinical-stage biotechnology companies incur substantial net losses for extended periods due to high R&D costs, similar to ALX Oncology.
• The reliance on equity financing for capital raises is a common practice in the biotech industry to fund development pipelines.
• The company's focus on CD47 inhibition is a recognized area of active research and development within oncology, with several competitors also pursuing this pathway.

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• The company's ability to fund operations and advance its pipeline impacts future shareholder value.
• Employees' job security is tied to the company's financial performance and ability to secure funding.
• Third-party manufacturers and service providers are dependent on the company's continued operations and payments.

Next Steps

• Advance evorpacept through multiple clinical trials in multiple indications.
• Pursue regulatory approval of evorpacept in solid tumors and hematological malignancies.
• Advance ALX2004 through a first-in-human trial.
• Continue preclinical and clinical development efforts.
• Obtain and maintain patent, trade secret, and other intellectual property protection and regulatory exclusivity.
• Manufacture supplies for preclinical studies and clinical trials.
• Add operational, financial, and management information systems to support ongoing operations as a public company.

Key Dates

Recommendation

ALX Oncology Holdings Inc. presents a mixed financial picture. While the company has reduced its net loss and R&D expenses, it continues to operate at a significant deficit with no approved products. The bolstered cash position from recent financing activities provides some runway, but the substantial ongoing capital requirements and the early stage of its pipeline candidates (evorpacept and ALX2004) introduce considerable risk. The company's reliance on future capital raises and the inherent uncertainties in drug development warrant a cautious approach. Therefore, a 'hold' recommendation is appropriate, pending more definitive clinical trial data and a clearer path to commercialization.

Keywords

biotechnology, oncology, clinical-stage, cancer therapy, drug development, evorpacept, CD47, ALX2004